Cargando…

A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy

Background: Inflammatory Bowel Disease (IBD) impacts millions worldwide, presenting a major challenge to healthcare providers and patients. The advent of biologic therapies has enhanced the prognosis, but many patients exhibit primary or secondary non-response, underscoring the need for rigorous mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sanket, Yarur, Andres J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607463/
https://www.ncbi.nlm.nih.gov/pubmed/37892715
http://dx.doi.org/10.3390/jcm12206577
_version_ 1785127547560787968
author Patel, Sanket
Yarur, Andres J.
author_facet Patel, Sanket
Yarur, Andres J.
author_sort Patel, Sanket
collection PubMed
description Background: Inflammatory Bowel Disease (IBD) impacts millions worldwide, presenting a major challenge to healthcare providers and patients. The advent of biologic therapies has enhanced the prognosis, but many patients exhibit primary or secondary non-response, underscoring the need for rigorous monitoring and therapy optimization to improve outcomes. Objective: This narrative review seeks to understand the role of therapeutic drug monitoring (TDM) in optimizing treatment for IBD patients, especially for those on combination therapies of biologics and immunomodulators. Methods: A comprehensive synthesis of the current literature was undertaken, focusing on the application, benefits, limitations, and future directions of TDM in patients receiving a combination of biologic therapies and immunomodulators. Results: While biological therapies have improved outcomes, rigorous monitoring and therapy optimization are needed. TDM has emerged as a pivotal strategy, enhancing outcomes cost-effectively while reducing adverse events. While most data pertain to monotherapies, TDM’s applicability also extends to combination therapy. Conclusion: TDM plays a crucial role in the treatment optimization of IBD patients on combination therapies. Further research is needed to fully understand its potential and limitations in the broader context of IBD management.
format Online
Article
Text
id pubmed-10607463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106074632023-10-28 A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy Patel, Sanket Yarur, Andres J. J Clin Med Review Background: Inflammatory Bowel Disease (IBD) impacts millions worldwide, presenting a major challenge to healthcare providers and patients. The advent of biologic therapies has enhanced the prognosis, but many patients exhibit primary or secondary non-response, underscoring the need for rigorous monitoring and therapy optimization to improve outcomes. Objective: This narrative review seeks to understand the role of therapeutic drug monitoring (TDM) in optimizing treatment for IBD patients, especially for those on combination therapies of biologics and immunomodulators. Methods: A comprehensive synthesis of the current literature was undertaken, focusing on the application, benefits, limitations, and future directions of TDM in patients receiving a combination of biologic therapies and immunomodulators. Results: While biological therapies have improved outcomes, rigorous monitoring and therapy optimization are needed. TDM has emerged as a pivotal strategy, enhancing outcomes cost-effectively while reducing adverse events. While most data pertain to monotherapies, TDM’s applicability also extends to combination therapy. Conclusion: TDM plays a crucial role in the treatment optimization of IBD patients on combination therapies. Further research is needed to fully understand its potential and limitations in the broader context of IBD management. MDPI 2023-10-17 /pmc/articles/PMC10607463/ /pubmed/37892715 http://dx.doi.org/10.3390/jcm12206577 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Patel, Sanket
Yarur, Andres J.
A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
title A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
title_full A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
title_fullStr A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
title_full_unstemmed A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
title_short A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
title_sort review of therapeutic drug monitoring in patients with inflammatory bowel disease receiving combination therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607463/
https://www.ncbi.nlm.nih.gov/pubmed/37892715
http://dx.doi.org/10.3390/jcm12206577
work_keys_str_mv AT patelsanket areviewoftherapeuticdrugmonitoringinpatientswithinflammatoryboweldiseasereceivingcombinationtherapy
AT yarurandresj areviewoftherapeuticdrugmonitoringinpatientswithinflammatoryboweldiseasereceivingcombinationtherapy
AT patelsanket reviewoftherapeuticdrugmonitoringinpatientswithinflammatoryboweldiseasereceivingcombinationtherapy
AT yarurandresj reviewoftherapeuticdrugmonitoringinpatientswithinflammatoryboweldiseasereceivingcombinationtherapy